Exhibit 3.1
RAPT THERAPEUTICS, INC.
AMENDEDAND RESTATED
CERTIFICATEOF INCORPORATION
OF
RAPT THERAPEUTICS, INC.
Brian Wong hereby certifies that:
ONE: The date of filing of the original Certificate of Incorporation of this company with the Secretary of State of the State of Delaware was March 4, 2015 under the name FLX Bio, Inc.
TWO: Heis the duly elected and acting President and Chief Executive Officer of RAPT Therapeutics, Inc., a Delaware corporation.
THREE: The Certificate of Incorporation of this company is hereby amended and restated to read as follows:
I.
The name of this company isRAPT THERAPEUTICS, INC.(the “Company”).
II.
The address of the registered office of this Company in the State of Delaware is 3500 S DuPont Highway, Dover, DE 19901 and County of Kent, and the name of the registered agent of this Company in the State of Delaware at such address is Incorporating Services, Ltd.
III.
The purpose of this Company is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law (“DGCL”).
IV.
A. This Company is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which the Company is authorized to issue is 550,000,000 shares. 500,000,000 shares shall be Common Stock, each having a par value of $0.0001. 50,000,000 shares shall be Preferred Stock, each having a par value of $0.0001.
B. The Preferred Stock may be issued from time to time in one or more series. The Board of Directors of the Company (the “Board of Directors”) is hereby expressly authorized to provide for the issue of all of any of the shares of the Preferred Stock in one or more series, and to fix the number of shares and to determine or alter for each such series, such voting powers, full or limited, or no voting powers, and such designation, preferences, and relative, participating, optional, or other rights and such qualifications, limitations, or restrictions thereof, as shall be stated and expressed in the resolution or resolutions adopted by the Board of Directors providing for the issuance of such shares and as may be permitted by the DGCL. The Board of Directors is also expressly authorized to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to the adoption of the resolution originally fixing the number of shares of such series. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority
1